1. Academic Validation
  2. Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein

Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein

  • Bioorg Med Chem Lett. 2014 Mar 15;24(6):1484-8. doi: 10.1016/j.bmcl.2014.02.010.
Andrew M Petros 1 Steven L Swann 2 Danying Song 2 Kerren Swinger 2 Chang Park 2 Haichao Zhang 2 Michael D Wendt 2 Aaron R Kunzer 2 Andrew J Souers 2 Chaohong Sun 3
Affiliations

Affiliations

  • 1 Research & Development, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, United States. Electronic address: andrew.petros@abbvie.com.
  • 2 Research & Development, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, United States.
  • 3 Research & Development, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, United States. Electronic address: chaohong.sun@abbvie.com.
Abstract

Apoptosis is regulated by the Bcl-2 Family of proteins, which is comprised of both pro-death and pro-survival members. Evasion of Apoptosis is a hallmark of malignant cells. One way in which Cancer cells achieve this evasion is thru overexpression of the pro-survival members of the Bcl-2 Family. Overexpression of Mcl-1, a pro-survival protein, has been shown to be a resistance factor for Navitoclax, a potent inhibitor of Bcl-2 and Bcl-xL. Here we describe the use of fragment screening methods and structural biology to drive the discovery of novel Mcl-1 inhibitors from two distinct structural classes. Specifically, cores derived from a biphenyl sulfonamide and salicylic acid were uncovered in an NMR-based fragment screen and elaborated using high throughput analog synthesis. This culminated in the discovery of selective and potent inhibitors of Mcl-1 that may serve as promising leads for medicinal chemistry optimization efforts.

Keywords

Apoptosis; BCL; FBDD; FBLD; Fragment-based; MCL-1; NMR.

Figures
Products